Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.
NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial active not recruiting, primary completion Feb 2026. No results released; all sources indicate topline data expected mid-2026. No public readout available.
Found Apr 6, 2026, 2:58 PMReviewed Apr 6, 2026, 3:00 PM
NO_DECISIONDismissed95% confidenceGrok 4.20 (xAI)
Will the results be positive?
No topline results released; trial ongoing with expected Q2 2026 readout. No positive/negative framing available for this exact trial.
Found Apr 6, 2026, 2:09 PMReviewed Apr 6, 2026, 2:25 PM
NO_DECISIONDismissed90% confidencemanual-chat-review
Will the results be positive?
ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.
Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:32 PM
NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific efficacy readout is public yet. As of March 23, 2026, Avalo still said Phase 2 LOTUS topline data were expected in Q2 2026, and a clinical trial listing shows NCT06603077 as ongoing with no results posted. Without an actual readout, positive vs negative cannot be determined.
Found Apr 3, 2026, 4:08 PMReviewed Apr 3, 2026, 4:47 PM
NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No public efficacy readout was found. Sponsor materials still described NCT06603077/LOTUS as ongoing, with topline data only anticipated in Q2/mid-2026 as of March 23, 2026. Without trial-specific results or sponsor framing, the outcome cannot be classified positive or negative.
Found Apr 1, 2026, 7:12 PMReviewed Apr 1, 2026, 7:16 PM